Viatris (VTRS) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Viatris (VTRS)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

15.37

-0.00 (0.00%)

as of Jun 18, 2026, 7:59:59 pm Market Open.

23 watching

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly

The pharma company produces Lipitor as one of its brands. It has embarked on a divestiture strategy that is allowing it to focus on core competencies and reduce costs. The are on target for $450 million in new product launches. It trades at 7x earnings and below book value. Cash reserves are growing as debt is aggressively retired. Its dividend is backed by a payout ratio under one-third of cash flow. We recommend placing a stop-loss at $8.50, looking to achieve $41 -- upside potential of 30%. Yield 4.5%

(Analysts’ price target is $14.11)

BUY

Share price flat, but owns shares.
Excellent business within healthcare sector.
Getting into new business lines.
4% dividend yield with lots of free cash flow.
Share buybacks good for shareholders.
Trading at 4x earnings.

RISKY

Product of recent merger of two separate pharma business'.
New CEO - remains to be seen whether he will preform.
Would like to see stabilization on business before investing.
Too early to invest.

TOP PICK

It is the cheapest stock in their portfolio at 4X earnings, a pharma company formed by a joint venture. Its investment grade bond issues are in rock solid shape. It sold a division for $2 billion and will use the cash for a couple of acquisitions in eye wear and to buy back stock. There are potential sales of other smaller divisions so there could be more buybacks plus paying down debt. The dividend yield is 4.1%. Has a low price due to a couple of disappointing quarters but numbers have been solid since. Also revenues have been flat-lining.
Buy 4 Hold 10 Sell 0

(Analysts’ price target is $13.09)

DON'T BUY

Global healthcare, mix of branded drugs and generics. Drug business has had a good run, but there's going to be significant pushback on the outsized profits, both globally and in the US. He prefers medical devices.

PAST TOP PICK

(A Top Pick Jan 27/22, Down 17%) It sold a division for $2 billion with a chunk of that money going to the purchase of a couple of eye-care companies. It is trading at 4X earnings and buying back lots of stock. It covers a number of areas including oncology, the central nervous system, anesthetics and will narrow this down to areas such as diabetes and cardio vascular which have good growth ahead of them.

BUY

Pharmaceutical company that sells generic drugs. Healthy dividend yield and cash flow. About to close on M&A deal. Big question is whether company will return capital to shareholders (share buybacks). Shares very cheap at current price.

HOLD

Trading at 4x earnings. Disappointed Wall Street. Finally stabilized earnings. Asset sale later this year will bring in a fair bit of money. He anticipates a share buyback, decent cashflow, decent dividend to continue. Strategy becoming more apparent.

BUY

Later this year they will complete the sale of a business and the company could (probably) buy back 10% of shares with that cash. Be patient. Trades at only 3-4x earnings. So a buyback will be a big boost to shares. Early on their reports disappointed but lately has been alright. This flies under the radar.

BUY

It's the cheapest stock he owns, trading at 3x earnings. They generate fresh cash flow. They close the sale in late 2022 of one of their divisions. He expects them to use a major share buyback with those proceeds, and a bump in the share price finally. This is an incredible value stock or everybody is missing something. We'll see.

DON'T BUY

Once they spun out their biosimilar business, he sold. Saw lots of debt, drugs coming off patent and pricing pressure, not a lot of growth. Value trap, even at these levels.

HOLD

Underperformer. Profitable, free cashflow positive. Out of favour. Profits from sale of biosimilar business will be used to buy back shares, which he approves of. Compellingly cheap at 3x earnings. Paying down debt.

HOLD

Cheapest stock in his portfolio, at a PE of 4. Free cashflow and dividend payer. Market didn't like lukewarm guidance. Either he's missing something, or it won't take much for the stock to outperform.

DON'T BUY

Includes boring drugs, which provide consistent cashflows. Bit of growth in its biosimilar business, but talk of selling that. Range bound, limited growth, fair amount of debt, but tolerable for the type of assets. Low margin generics are more sensitive to inflationary risks. Dividend is probably safe.

TOP PICK

Huge free cashflow. PE ratio is 4, not 14, but 4. Stock disappointed investors last year, Q3 was above expectations, expects Q4 to be strong. Needs very little to go right for them to do well. Went up in the recent down market. How can you not buy it? Yield is 3.25%. (Analysts’ price target is $18.62)

Showing 1 to 15 of 23 entries

Viatris (VTRS) Frequently Asked Questions

What is Viatris stock symbol?

Viatris is a American stock, trading under the symbol VTRS (previously VTRS-Q on Stockchase) on the NASDAQ (VTRS). It is usually referred to as NASDAQ:VTRS or VTRS

Is Viatris a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on VTRS (previously VTRS-Q on Stockchase) on Stockchase. Read the latest expert commentary for Viatris.

Is Viatris a good investment or a top pick?

Viatris was recommended as a Top Pick by Lorne Steinberg on 2022-01-27. Read the latest stock experts ratings for Viatris.

Why is Viatris stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Viatris.

Is Viatris worth watching?

Viatris is followed by 23 investors on Stockchase and is a trending stock that is worth watching.

What is Viatris stock price?

On 2026-06-18, Viatris (VTRS) stock closed at a price of $15.37.

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Viatris (VTRS)

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Viatris(VTRS)

Viatris(VTRS)

Viatris(VTRS)

Viatris(VTRS)

Viatris(VTRS)

Viatris(VTRS)

Viatris(VTRS)

Viatris(VTRS)

Viatris(VTRS)

Viatris(VTRS)

Viatris(VTRS)

Viatris(VTRS)

Viatris(VTRS)

Viatris(VTRS)

Viatris(VTRS)